Day 1 | Friday, 24th May 2024
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
from 09:30
Registration
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
10:45
Welcome
Scientific committee
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-4.png)
11:00-1:00
Session 1
The germinal center reaction as
a catalyst for lymphoma development
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
Chair
![](https://www.lymphoma-symposium.de/wp-content/uploads/Reinhardt-Christian_250x250.png)
Christian Reinhardt
University Hospital Essen (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
11:00
![](https://www.lymphoma-symposium.de/wp-content/uploads/Dalla-Favera_Riccardo_250x250.png)
Role of Super-enhancer
Hypermutation in the
Pathogenesis of Diffuse
Large B cell Lymphoma
Riccardo Dalla-Favera,
Columbia University New York (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
11:25
![](https://www.lymphoma-symposium.de/wp-content/uploads/Pasqualucci_Laura_250x250.png)
Genetics-driven epigenetic disruption
of the germinal center program
in B cell lymphomas
Laura Pasqualucci,
Columbia University New York (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
11:50
![](https://www.lymphoma-symposium.de/wp-content/uploads/Kueppers_Ralf_250x250.png.png)
Aspects of Hodgkin lymphoma biology
Ralf Küppers,
University Hospital Essen (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
12:15
![](https://www.lymphoma-symposium.de/wp-content/uploads/Photo_Dinis.jpg)
Modelling Sporadic Oncogenic Events
in Lympho magenesis
Dinis Calado,
The Francis Crick Institute London (UK)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
12:50
Discussion
1:00-2:00
Break
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-7.png)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-4.png)
2:00-4:00
Session 2
Epigenetic rewiring as a driver
and target of lymphomagenesis
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
Chair
![](https://www.lymphoma-symposium.de/wp-content/uploads/Borchmann_Peter_1x1.jpg)
Peter Borchmann
University Hospital Cologne (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
2:00
![](https://www.lymphoma-symposium.de/wp-content/uploads/Melnick_Ari.png)
Mechanisms and therapeutic targeting
of the malignant immune system
Ari M. Melnick,
Weill Cornell Medicine New York (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
2:25
![](https://www.lymphoma-symposium.de/wp-content/uploads/Al_Sawafi_Othmann.jpg)
Development of small molecules
for epigenetic targets
Othman Al-Sawaf,
Universitätsklinikum Köln (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
2:50
![](https://www.lymphoma-symposium.de/wp-content/uploads/Schmitt_Clemens_250x250.png)
Harnessing state switches
in aggressive B-cell lymphoma
Clemens Schmitt,
Charité – University Hospital Berlin (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
3:15
![](https://www.lymphoma-symposium.de/wp-content/uploads/Siebert_Reiner_250x250.png)
DNA-methylation based classification
of lymphomas: A tool to come?
Reiner Siebert,
Ulm University Hospital (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
3:40
![](https://www.lymphoma-symposium.de/wp-content/uploads/Alizadeh_Ash_250x250.png)
Remote contribution
Toward the noninvasive characterization
of lymphomas & their microenvironments
Ash A. Alizadeh,
Stanford University / Stanford
Comprehensive Cancer Center (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-4.png)
4:00-6:00
Poster presentation and
Get together
Day 2 | Saturday, 25th May 2024
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-4.png)
8:00-10:00
Session 3
Genetic rewiring encodes actionable
vulnerabilities in lymphoma
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
Chair
![](https://www.lymphoma-symposium.de/wp-content/uploads/Dietrich_Sascha_250x250.png)
Sascha Dietrich
University Hospital Düsseldorf (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
8:00
![](https://www.lymphoma-symposium.de/wp-content/uploads/Shipp_Margaret-e1700585802139.jpg)
Genetic bases of immune evasion in lymphoma
Margaret Shipp,
Dana Farber/Harvard Cancer Center
Boston (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
8:25
![](https://www.lymphoma-symposium.de/wp-content/uploads/Staudt_at_home_portrait_crop.jpg)
Curing aggressive lymphomas
with aggressive combinations
of targeted agents
Louis Staudt,
National Cancer Institute Bethesda (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
8:50
![](https://www.lymphoma-symposium.de/wp-content/uploads/Chapuy-Bjoern.jpg)
Actionable Alterations in LBCL
Björn Chapuy,
Charité University Medicine Berlin (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
9:15
![](https://www.lymphoma-symposium.de/wp-content/uploads/Oellerich_Thomas_250x250.png)
Elucidation of Lymphoma Proteogenotypes
Thomas Oellerich,
University Hospital Frankfurt (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
9:50
Discussion
10:00-10:30
Break
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-7.png)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-4.png)
10:30-12:00
Session 2
Epigenetic rewiring as a driver
and target of lymphomagenesis
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
Chair
![](https://www.lymphoma-symposium.de/wp-content/uploads/Borchmann_Peter_1x1.jpg)
Peter Borchmann
University Hospital Cologne (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
02:00
![](https://www.lymphoma-symposium.de/wp-content/uploads/Melnick_Ari.png)
Ari M. Melnick
Weill Cornell Medicine New York (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
02:25
![](https://www.lymphoma-symposium.de/wp-content/uploads/Knapp_Stefan_250x250.png)
Stefan Knapp
Goethe-University Frankfurt (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
02:50
![](https://www.lymphoma-symposium.de/wp-content/uploads/Schmitt_Clemens_250x250.png)
Clemens Schmitt
Charité – University Hospital Berlin (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
03:15
![](https://www.lymphoma-symposium.de/wp-content/uploads/Siebert_Reiner_250x250.png)
Rainer Siebert
Ulm University Hospital (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
09:40
Short talk II
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
09:50
Discussion
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-4.png)
10:30-12:30
Session 4
The next frontier: harnessing the
immune system for lymphoma therapy
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
Chair
![](https://www.lymphoma-symposium.de/wp-content/uploads/von-Tresckow-PD-Dr.-Bastian_250x250.png)
Bastian von Tresckow
University Hospital Essen (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
10:30
![](https://www.lymphoma-symposium.de/wp-content/uploads/Westin_Jason_250x250.png)
Chemotherapy free approaches
in first line LBCL – a dream or a reality?
Jason Westin,
University of Texas MD Anderson Cancer
Center Houston (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
10:55
![](https://www.lymphoma-symposium.de/wp-content/uploads/2wendy-beguelin-1024x1024.jpg)
Enhancing immunotherapies for germinal
center-derived B cell lymphomas by
EZH2 inhibition
Wendy Béguelin,
Weill Cornell Medicine New York, (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
11:20
![](https://www.lymphoma-symposium.de/wp-content/uploads/ullrich-roland.png)
Multi-omic profiling of CAR T cell
treated aggressive B-cell
lymphoma reveals a CSF1R+
myeloid-monocytic cell
compartment mediating
CAR T cell resistance
Roland Ullrich,
University Hospital Cologne (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
11:45
![](https://www.lymphoma-symposium.de/wp-content/uploads/Budde_Elisabeth_250x250.png)
Bispecific T Cell Engagers
in Follicular Lymphoma:
Promises and Path Ahead
Elisabeth Budde,
City of Hope National MedicalCenter Duarte (USA)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
12:10
![](https://www.lymphoma-symposium.de/wp-content/uploads/Dietrich_Sascha_250x250.png)
Multimodal and spatially resolved profiling
identifies distinct patterns of T cell infiltration
in nodal B cell lymphoma entities
Sascha Dietrich,
University Hospital Düsseldorf (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
12:35
Discussion
12:45-1:45
Break
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-7.png)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-4.png)
1:45-3:30
Session 5
Mechanisms of resistance and
definition of high-risk DLBCL
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
Chair
![](https://www.lymphoma-symposium.de/wp-content/uploads/Kueppers_Ralf_250x250.png.png)
Ralf Küppers
University Hospital Essen (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
1:55
![](https://www.lymphoma-symposium.de/wp-content/uploads/Davies_Andrew_250x250.png)
Mechanisms of resistance and
definition of high-risk DLBCL
Andrew Davies,
Southampton General Hospital (UK)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
2:20
![](https://www.lymphoma-symposium.de/wp-content/uploads/staber.png)
Overcoming therapy resistance
through single-cell functional precision
medicine approaches
Philipp Staber,
Medical University of Vienna (AUT)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
2:45
![](https://www.lymphoma-symposium.de/wp-content/uploads/Reinhardt-Christian_250x250.png)
Autochthonous mouse models of DLBCL
enable in vivo genetic screening and
serve as a platorm for preclinical validation
of actionable vulnerabilities
Christian Reinhardt,
University Hospital Essen (GER)
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-3.png)
3:10
Discussion
![](https://www.lymphoma-symposium.de/wp-content/uploads/Ellipse-7.png)
3:30
Closing remarks
Farewell and Goodbye
Status 05/2024, subject to change.